Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Germline Genetic Testing Assesses Inherited Risk for Myeloid Malignancies

By LabMedica International staff writers
Posted on 26 Dec 2019
Inherited risk for hematologic malignancies was historically thought to be relatively rare; however, the increased use of next-generation sequencing has identified more patients with germline genetic mutations that are known to increase cancer risk.

Older acute myeloid leukemia (AML) patients are not typically offered germline genetic testing to assess their inherited risk for myeloid malignancies. More...
When cancer risk mutations are identified in patients with hematologic malignancies, this knowledge can inform treatment, and help determine whether family members, who may or may not have inherited the same mutation, can be donors for stem cell transplantation.

Scientists at Foundation Medicine (Cambridge, MA, USA) and their colleagues analyzed 179 AML participants who provided tumor samples from bone marrow or blood, and normal samples from saliva or skin for genetic analysis. Tumor and normal samples were analyzed by Foundation Medicine using its FoundationOne Heme next-generation sequencing test, and the normal samples were analyzed by Oregon Health & Science University (OHSU, Portland, OR, USA) on its GeneTrails hematological malignancies NGS panel.

The results of the tests conducted independently by the two laboratories yielded a 14% prevalence of germline pathogenic variants, or 27 mutations in 24 AML patients. The teams classified 181 variants of unknown significance in 102 patients, a prevalence of 57%. There were seven variant calls that were discordant between the two groups and were excluded because a consensus determination could not be reached.

DDX41 mutations, which have been previously described in older AML patients, were identified in five patients and were the most commonly identified pathogenic germline risk marker in the study. Mutations were also identified in CHEK2, SBDS, MPL, BRCA2, and the Fanconi anemia-associated genes FANCA and FANCL, among others. However, the vast majority of mutations identified in the analysis were variants of uncertain significance (VUS), and the most common were VUS in DOCK8 and CREBBP with a prevalence of more than 5%.

The investigators compared the median variant allele frequency of somatic mutations in skin and saliva samples from 37 patients, and found that the variant allele frequency was significantly lower in the former (8% versus 20%). They determined, as other groups have, that saliva may not be a good option when collecting "matched" normal samples from patients at the time of AML diagnosis.

Uma Borate, MD, MS, an Oncologist and senior author of the study, said, “If we suspect an inherited predisposition to AML, we really want to be careful about the donors we're using, particularly if they're family members. The risk is the donors could have the same mutation and pass that on to the patient in these stem cells and that those stem cells may go on to develop the same malignancy.” The study was presented at the American Society of Hematology annual meeting held December 7-10, 2019 in Orlando, FL, USA.

Related Links:
Foundation Medicine
Oregon Health & Science University



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Left is the original cell image and right is same cell image zoomed in and rendered in the special imaging software (Photo courtesy of FIU)

Brain Inflammation Biomarker Detects Alzheimer’s Years Before Symptoms Appear

Alzheimer’s disease affects millions globally, but patients are often diagnosed only after memory loss and other symptoms appear, when brain damage is already extensive. Detecting the disease much earlier... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.